Tuesday, November 19, 2024 8:13:32 AM
Sure, keep in mind this is just my rough calculations and based on hypothetical scenarios:
$75M Current Products launched
$75M 5 ANDAs launching this is a conservative 7.5% market share (APAP/Oxy, Hydro/APAP, Methadone, Apap and Codeine, methotrexate)
$860M, this is the wild card, 20% of the current 4.3B, with the drug being in shortage the price should stay elevated and if we have a new API with no supply
issues.
$1.01B in sales assume a 35% profit margin, assumptions again, I think this may be higher as the margins for Vyvanse will be better, but I am going conservative
$353.5M/Shares Outstanding
$0.333c/share
PE 25 is $8.33
PE 35 is $11.67
This is all hypothetical and of course if everything goes perfect but shows the potential and keep in mind this does not include any new drugs filed and in the pipeline. This is why I am excited!! Fun to play with numbers, time will tell!!
$75M Current Products launched
$75M 5 ANDAs launching this is a conservative 7.5% market share (APAP/Oxy, Hydro/APAP, Methadone, Apap and Codeine, methotrexate)
$860M, this is the wild card, 20% of the current 4.3B, with the drug being in shortage the price should stay elevated and if we have a new API with no supply
issues.
$1.01B in sales assume a 35% profit margin, assumptions again, I think this may be higher as the margins for Vyvanse will be better, but I am going conservative
$353.5M/Shares Outstanding
$0.333c/share
PE 25 is $8.33
PE 35 is $11.67
This is all hypothetical and of course if everything goes perfect but shows the potential and keep in mind this does not include any new drugs filed and in the pipeline. This is why I am excited!! Fun to play with numbers, time will tell!!
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
